Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prophase Labs ( (PRPH) ) has provided an update.
On November 21, 2025, ProPhase Labs, Inc. disclosed that a civil action filed against it in 2023 had been unsealed by court order on November 4, 2025. The unsealing is a procedural step under the False Claims Act, and the company was unaware of the action until November 19, 2025. ProPhase Labs has not been served with the complaint and has received no indication of governmental intervention. The company denies any wrongdoing, maintains its compliance standards, and intends to defend itself vigorously. It also notes that a separate private dispute with Dr. Hennrick was resolved in April 2024. The company does not expect the unsealed matter to impact its operations.
The most recent analyst rating on (PRPH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Underperform.
Prophase Labs faces significant financial and technical challenges, with declining revenues, negative profitability, and bearish technical indicators. The negative P/E ratio further highlights valuation concerns. While there are some strategic initiatives in place, the overall outlook remains weak, necessitating substantial improvements to enhance financial stability and investor confidence.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
Average Trading Volume: 1,985,045
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.31M
For a thorough assessment of PRPH stock, go to TipRanks’ Stock Analysis page.